Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839917 | 0.75 | LDHA (0.48) | AKR1C3AKR1C2PSEN1PSEN2APH1B | |
| SCHEMBL10895409 | 0.75 | PSEN1 (0.54) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL14000031 | 0.72 | MEN1 (0.41) | AKR1C3AKR1C2CES2FFAR1TRPM8 | |
| SCHEMBL2647603 | 0.71 | APP (0.44) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL298387 | 0.69 | AKR1C3 (0.68) | AKR1C3AKR1C2AKR1C4AKR1C1PSEN1 | |
| SCHEMBL1864403 | 0.69 | GRIK1 (0.55) | IDO1PPARG | |
| SCHEMBL12629396 | 0.69 | GRIK1 (0.55) | IDO1PPARG | |
| SCHEMBL12629289 | 0.69 | GRIK1 (0.55) | IDO1PPARG | |
| SCHEMBL12762358 | 0.69 | GRIK1 (0.55) | IDO1PPARG | |
| SCHEMBL892902 | 0.69 | IDO1 (0.51) | CES2IDO1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2009046371-A1 | METHODS OF TREATING METABOLIC DISEASES | METABOLEX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046371-A1 | METHODS OF TREATING METABOLIC DISEASES | METABOLEX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1716116-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080340-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | GPR119, SLC5A1, AADAC | AKR1C3 361/4885AKR1C2 234/4885AKR1B10 622/4885 |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | PPARG, PPARA, PPARD | AKR1C3 961/4885AKR1C2 644/4885AKR1B10 840/4885 |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | SLC5A1, GPR119, SLC5A2 | AKR1C3 444/4885AKR1C2 260/4885AKR1B10 640/4885 |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | PPARG, PPARA, PPARD | AKR1C3 140/4885AKR1C2 137/4885AKR1B10 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.